Aduro BioTech, Inc. (ADRO) At $7.45 Forms Bottom; GUANGDONG INVESTMENT LTD ORDINARY SHARES (GGDVF) Shorts Down By 50.04%

Guangdong Investment Limited (OTCMKTS:GGDVF) Logo

Aduro BioTech, Inc. (ADRO) formed multiple bottom with $7.23 target or 3.00% below today’s $7.45 share price. Aduro BioTech, Inc. (ADRO) has $603.50M valuation. The stock decreased 0.67% or $0.05 during the last trading session, reaching $7.45. About 252,485 shares traded. Aduro BioTech, Inc. (NASDAQ:ADRO) has declined 11.85% since April 18, 2017 and is downtrending. It has underperformed by 23.40% the S&P500.

GUANGDONG INVESTMENT LTD ORDINARY SHARES (OTCMKTS:GGDVF) had a decrease of 50.04% in short interest. GGDVF’s SI was 725,400 shares in April as released by FINRA. Its down 50.04% from 1.45M shares previously. The SI to GUANGDONG INVESTMENT LTD ORDINARY SHARES’s float is 0.03%. The stock decreased 0.63% or $0.01 during the last trading session, reaching $1.57. About shares traded. Guangdong Investment Limited (OTCMKTS:GGDVF) has 0.00% since April 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Guangdong Investment Limited engages in investment holding, water resources, property investment and development, department store operation, energy projects investment, road and bridge operation, and hotel operation and management businesses. The company has market cap of $10.00 billion. The companyÂ’s Property Investment and Development segment invests in various properties, such as shopping malls, office buildings, and hotels in Hong Kong and Mainland China; and engages in the development of properties in Mainland China. It has a 14.02 P/E ratio. This segment also provides property management services for various commercial properties.

Analysts await Aduro BioTech, Inc. (NASDAQ:ADRO) to report earnings on May, 1. They expect $-0.30 EPS, up 6.25% or $0.02 from last year’s $-0.32 per share. After $-0.35 actual EPS reported by Aduro BioTech, Inc. for the previous quarter, Wall Street now forecasts -14.29% EPS growth.

Among 10 analysts covering Aduro Biotech (NASDAQ:ADRO), 8 have Buy rating, 1 Sell and 1 Hold. Therefore 80% are positive. Aduro Biotech has $68 highest and $8 lowest target. $25.61’s average target is 243.76% above currents $7.45 stock price. Aduro Biotech had 21 analyst reports since August 19, 2015 according to SRatingsIntel. Bank of America maintained the shares of ADRO in report on Friday, March 2 with “Underperform” rating. The stock of Aduro BioTech, Inc. (NASDAQ:ADRO) earned “Buy” rating by Oppenheimer on Monday, October 30. The firm has “Underperform” rating by Bank of America given on Tuesday, March 15. Oppenheimer downgraded the shares of ADRO in report on Tuesday, December 1 to “Perform” rating. As per Wednesday, August 19, the company rating was initiated by Leerink Swann. The rating was upgraded by Zacks on Thursday, September 3 to “Hold”. The stock of Aduro BioTech, Inc. (NASDAQ:ADRO) has “Buy” rating given on Wednesday, September 27 by H.C. Wainwright. The stock has “Buy” rating by Cowen & Co on Tuesday, July 18. The firm has “Buy” rating by Roth Capital given on Thursday, August 27. H.C. Wainwright maintained Aduro BioTech, Inc. (NASDAQ:ADRO) on Tuesday, October 17 with “Buy” rating.

Aduro BioTech, Inc. (NASDAQ:ADRO) Ratings Chart